– USA, CA – Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of John McDonald to its Board as an independent Director, effective September 7, 2022.
About John F. McDonald
Currently, John McDonald serves as Corporate VP, Global R&D Business Development, for Novo Nordisk A/S, where he leads R&D business development activities and investment strategies, as well as participates in the creation of research, early development, and therapeutic pipeline diversification and augmentation strategies. From 2011 to 2018, Mr. McDonald was VP, of Business Development, at Biogen Inc., where he led business development and negotiated numerous strategic alliances, licenses and acquisitions. From 2006 to 2011, Mr. McDonald served as Managing Director at MPM Capital LP, serving as the primary business development and asset strategy resource for multiple portfolio companies. Prior to 2006, Mr. McDonald held business development, corporate strategy, and legal roles of increasing responsibility at various biopharmaceutical companies, including Millennium Pharmaceuticals Inc., Genzyme Corp and Genentech, Inc.
Mr. McDonald holds a J.D. from the University of California Hastings College of the Law and an M.B.A. and B.S. from the Haas School of Business, University of California, Berkeley.
About Geron
Geron is a late-stage clinical biopharmaceutical company focused on developing and potentially commercializing a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company is currently conducting two Phase 3 clinical trials: IMerge in lower-risk myelodysplastic syndromes and IMpactMF in relapsed/refractory myelofibrosis.
For more information: https://www.geron.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
